Program
CD19 CAR-T cells
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lupus Erythematosus, Systemic, led by Chongqing Precision Biotech.
Furthest: phase 2, since Feb 13, 20203 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Precision Biotech | 32 open or running | phase 2since Feb 13, 2020 | Feb 13, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2020First studies: 2 phase 2 studies in LeukemiaFirst studyNCT04271800, NCT04271410
- Dec 11, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07331467 · 18 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07331467Lupus Erythematosus, Systemic · China | 1 | Recruiting | Jul 2026 | 18 |
| NCT04271800Leukemia · China | 2 | UNKNOWN | Dec 31, 2023 | 40 |
| NCT04271410Leukemia · China | 2 | Recruiting | Dec 31, 2023 | 80 |
How it is read
Names in the registry
- “CD19 CAR-T cells”, 3 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.